Improving lung cancer treatment for veterans using immunotherapy
Official title: Repositioning Immunotherapy in Veterans with Lung Cancer
Funded at Veterans Health Administration · NIH-10916686 · Data updated 2026-11-12
This study is looking at a new treatment plan that combines immunotherapy and chemotherapy before surgery for veterans with advanced lung cancer, hoping to make the treatment easier to handle and help them live longer without the cancer getting worse.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veterans Health Administration NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| NIH project number | 1I01CX002665-01A2 |
| Project ID | NIH-10916686 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are veterans diagnosed with unresectable Stage III non-small cell lung cancer who are seeking alternative treatment options.
✕Less likely to help
Patients with resectable lung cancer or those who are not veterans may not benefit from this research.
What this research studies
This research investigates the use of neoadjuvant immunotherapy combined with chemotherapy for veterans diagnosed with unresectable Stage III lung cancer. The approach aims to enhance treatment tolerance and improve progression-free survival rates by administering immunotherapy before surgery. The study will also explore the use of PET-adaptive radiotherapy to optimize treatment delivery and minimize side effects. By focusing on veterans, the research addresses a critical need for more effective and manageable treatment options in this population.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and better quality of life for veterans with lung cancer.
How similar studies have gone: Previous research has shown promising results with neoadjuvant immunotherapy in other cancers, suggesting potential success in this approach for lung cancer.
Where this research is happening
-
Veterans Health Administration
Ann Arbor, United States Active
Researchers
- Principal investigator: Ramnath, Nithya — Veterans Health Administration
- Study coordinator: Ramnath, Nithya
Related research
Other NIH-funded projects on the same topics.
-
Biomarkers to predict and improve immunotherapy response in lung cancer
This grant aims to find gene-based markers that predict which NSCLC patients will benefit from immunotherapy and to uncover ways to make treatment work better for those who don’t respond.
-
Improving immunotherapy for lung cancer
A team at Emory University is exploring ways to boost how well PD-1–targeted therapies work for people with non-small cell lung cancer.
-
Targeting GARP-TGFβ to Improve Immunotherapy in NSCLC
A new antibody approach aims to block a key TGFβ-related pathway in the tumor environment to help people with non-small cell lung cancer respond better to therapy.
-
Targeting DHX9 to boost viral-like immune response in Small Cell Lung Cancer
A scientist team is testing whether blocking a protein called DHX9 can make aggressive small cell lung cancer more visible to the immune system and more responsive to immunotherapy.
-
Intratumoral microbiota and immune predictors of response to immunotherapy in lung cancer
A scientist team will study whether specific microbes inside lung tumors and immune cells can predict who will respond to immunotherapy in lung cancer.
-
Harnessing Exercise to Improve Immunotherapy for Lung Cancer
A clinical study tests whether a structured exercise program can boost how well lung cancer patients respond to immunotherapy and reduce treatment-related side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.